Streetbeat News

Analyst Ratings

CHPT

RF Lafferty analyst Jaime Perez maintains a 'Buy' rating on ChargePoint Holdings (NYSE:CHPT) but has lowered the price target from $19 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:19 pm

NKE

Williams Trading analyst Sam Poser has maintained a 'Sell' rating on Nike (NYSE:NKE) and lowered the price target from $95 to $91.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:16 pm

GOLF

Tigress Financial analyst Ivan Feinseth maintains a 'Buy' rating on Acushnet Hldgs (NYSE:GOLF) and raises the price target from $62 to $68.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:14 pm

CHPT

TD Cowen analyst Gabe Daoud maintains an Outperform rating on ChargePoint Holdings (NYSE:CHPT) but lowers the price target from $14 to $11.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:13 pm

DCTH

Canaccord Genuity analyst Arlinda Lee maintains a Buy rating on Delcath Systems (NASDAQ:DCTH) and raises the price target from $18 to $21.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:12 pm

HUBS

Canaccord Genuity analyst David Hynes maintains a 'Buy' rating on HubSpot (NYSE:HUBS) and raises the price target from $550 to $600.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:10 pm

PATH

Canaccord Genuity analyst Kingsley Crane maintains a 'Buy' rating on UiPath (NYSE:PATH) and raises the price target from $19 to $21.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:08 pm

ATNM

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Actinium Pharma (AMEX:ATNM) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 4:05 pm

ADMP

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has announced a name change to DMK Pharmaceuticals Corporation, reflecting a new strategic focus on advancing small molecules for the treatment of substance use disorders. The company's common stock is expected to trade under the new Nasdaq ticker symbol 'DMK' from September 8, 2023. The company is developing DPI-125, a novel molecule for the treatment of opioid use disorder and moderate to severe pain. DMK expects several potential significant milestones for DPI-125 by the end of 2024.

Portfolio Pulse from Happy Mohamed

September 07, 2023 | 4:02 pm

PDD

PDD Holdings' shares are trading lower following a short report from Grizzly Research.

Portfolio Pulse from Bill Haddad

September 07, 2023 | 4:02 pm